Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A et al (2021) Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors. JAMA Oncol 7(4):525–533. https://doi.org/10.1001/jamaoncol.2020.7987
2. Hayes DF (2021) Defining clinical utility of tumor biomarker tests: a clinician’s viewpoint. J Clin Oncol 39(3):238–248. https://doi.org/10.1200/JCO.1220.01572
3. Hertz DL, McShane LM, Hayes DF (2022) Defining clinical utility of germline indicators of toxicity risk: a perspective. J Clin Oncol 24(10):02209
4. Hertz DL (2022) Assessment of the clinical utility of pretreatment DPYD testing for patients receiving fluoropyrimidine chemotherapy. J Clin Oncol 15(10):00037
5. Ioannidis JP (2013) To replicate or not to replicate: the case of pharmacogenetic studies: have pharmacogenomics failed, or do they just need larger-scale evidence and more replication? Circ Cardiovasc Genet 6(4):413–418
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献